18.208.187.128
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Dry Eye/OSD

Clinical Trial on Wearable Eyelid Technology for Dry Eye Symptoms Meets Endpoints

Posted on

Data from a multicenter trial evaluating a wearable eyelid technology for dry eye were presented at the American Society of Cataract Refractive Surgery (ASCRS) Virtual annual meeting.

The prospective, randomized multicenter trial, enrolled 235 patients with dry eyes. Patients treated with TearCare achieved clinically meaningful improvements in symptoms of dry eye disease. Compared with a LipiFlow thermal pulsation system, more patients treated with TearCare experienced symptomatic relief.

“Dry eye is an increasingly common disease, and there is a significant unmet need for an effective treatment that provides significant symptomatic relief,” said Jennifer Loh, MD. “Having used TearCare for the past year, I have found that the procedure delivers rapid results and consistently high effectiveness for my dry eye patients. It is exciting and encouraging to see that the results of this randomized controlled trial are consistent with my real-world experience and underscore the reason I offer TearCare to my patients—notably that TearCare delivers more symptomatic relief for patients than any other options in this category, as evidenced by an unprecedented and high rate of subjects (72%) whose symptoms had clinically meaningful improvement by at least one OSDI category within a month.”

Reference

Loh J, et al.A novel, targeted, open eye, thermal therapy and meibomian gland clearance in treatment of dye eye: A randomized control trial (OLYMPIA). American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. May 16, 2020.

-Advertisement-
Related Articles
Compounded fixed-combination injection provides stable mydriasis during surgery
Aug 04, 2021
More research needed on link between strabismus and mental health disorders in kids
May 21, 2021
Patient demographics influence utilization of care for eye conditions
May 21, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-